You are here: Industry Insights > NIAID

News List

Rho Granted Extension by NIAID to Study Rate of COVID-19 Infection in US Children americanpharmaceuticalreview
July 30, 2021
Rho announced its Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, to help determine the rate of the new coronavirus infection in children and their families in the U.S. has been extended through April 2022.
Cerba Research Wins NIH Contract for Central Lab Services contractpharma
July 29, 2021
Cerba Research was awarded a five-year contract for clinical central lab services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
NexImmune Strengthens Management Team with Key Appointments firstwordpharma
July 15, 2021
NexImmune, Inc. (Nasdaq: NEXI) today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research
US begins testing mixed COVID-19 vaccine regimens europeanpharmaceuticalreview
June 04, 2021
A Phase I/II trial will enrol 150 individuals already vaccinated against COVID-19 with one vaccine and assess the safety and immunogenicity of a booster dose of a different COVID-19 vaccine.
First-in-human universal flu vaccine trial begins europeanpharmaceuticalreview
June 03, 2021
The US National Institutes of Health have begun a first-in-human trial to assess the safety and immunogenicity of a potential universal influenza vaccine candidate, FluMos-v1.
Trial to assess anti-CD14 antibody as treatment for hospitalised COVID-19 patients europeanpharmaceuticalreview
April 15, 2021
The trial will evaluate whether the novel IC14 anti-CD14 antibody can reduce recovery time and severity of COVID-19 symptoms in hospitalised patients.
NIH begins trial of Moderna’s Covid-19 variant vaccine pharmaceutical-technology
April 02, 2021
The US National Institutes of Health (NIH) has initiated dosing in a new Phase I clinical trial of Moderna’s investigational vaccine candidate, mRNA-1273.351, in adult subjects.
NIAID statement on AstraZeneca vaccine and AstraZeneca update worldpharmanews
March 24, 2021
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.
NIAID grants $2.5m to 12 institutes for bacteriophage therapy research pharmaceutical-business-review
March 12, 2021
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
Sagent Begins NIAID-Sponsored Study Investigating Outpatient COVID-19 Treatments americanpharmaceuticalreview
February 18, 2021
Sagent Pharmaceuticals announced Camostat mesilate, is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health ...

Previous page 1 2 3 4 5 Next page